QSAM Biosciences, Inc. is developing next-generation nuclear medicines for the treatment of cancer and related diseases. QSAM’s initial technology, CycloSam® (Samarium-153 DOTMP), is a clinical-stage bone targeting radiopharmaceutical developed by IsoTherapeutics Group LLC, pioneers in the nuclear medicine space who also developed the FDA-approved and commercially available Quadramet® (Samarium-153 EDTMP) radiopharmaceutical product, which is indicated for pain palliation. QSAM is led by an experienced executive team and Board of Directors that have completed dozens of FDA approvals and multiple successful biotech exits.
Company profile
Ticker
QSAM
Exchange
Website
CEO
J. Lloyd Breedlove
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Anpath Group, Inc., Q2Earth Inc., Q2Power Technologies, Inc., Telecomm Sales Network Inc
SEC CIK
Corporate docs
Subsidiaries
QSAM Therapeutics, Inc. • Q2Power Corp. ...
QSAM stock data
Latest filings (excl ownership)
DEFM14C
Information related to merger
11 Apr 24
PREM14C
Preliminary information related to merger
1 Apr 24
10-K
2023 FY
Annual report
20 Mar 24
8-K
QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals
7 Feb 24
8-K
Other Events
16 Jan 24
8-K
Receives $2 Million Pre-Closing Collaboration and Option Fee
14 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Unregistered Sales of Equity Securities
29 Sep 23
8-K
QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data
16 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
Latest ownership filings
SC 13D/A
Checkmate Strategic Capital 2, LLC
20 Feb 24
5
Charles Thomas Paschall
20 Feb 24
SC 13G/A
Strategic Planning Assets Ltd
20 Feb 24
SC 13G/A
GSB Holdings, Inc.
15 Feb 24
4/A
Douglas R Baum
14 Feb 24
4/A
Christopher M. Nelson
14 Feb 24
4/A
Jr. Charles J Link
14 Feb 24
4
Douglas R Baum
13 Feb 24
4
Christopher M. Nelson
13 Feb 24
4
Adam King
29 Jun 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2021
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 4.70 mm |
Total shares | 7.96 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Checkmate Strategic Capital 2 | 7.96 mm | $4.70 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Jun 23 | Adriann Sax | Common Stock | Grant | Acquire A | No | No | 0 | 10,455 | 0.00 | 10,455 |
23 Jun 23 | Christopher M. Nelson | Common Stock | Grant | Acquire A | No | No | 0 | 46,365 | 0.00 | 173,317 |
23 Jun 23 | Link Charles J. Jr. | Common Stock | Grant | Acquire A | No | No | 0 | 10,455 | 0.00 | 82,464 |
23 Jun 23 | Douglas R Baum | Common Stock | Grant | Acquire A | No | No | 0 | 72,276 | 0.00 | 375,547 |
23 Jun 23 | C Richard Piazza | Common Stock | Grant | Acquire A | No | No | 0 | 72,276 | 0.00 | 377,862 |
Press releases
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) launches strategic initiative focused on the manufacture of the highly sought after medical isotope Actinium-225 (Ac-225)
14 Mar 24
Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform
7 Feb 24
QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals
7 Feb 24